The disclosure relates to glucagon derivates comprising a surfactant. The surfactant may be N-omega-1’-alkyl beta-D-glucuronyl and it may be covalently linked to a lysine. The disclosure also relates to pharmaceutical compositions comprising these peptides and the use of them in the treatment of diseases such as diabetes or cardiovascular disease.